Literature DB >> 17138656

Bone morphogenetic protein and retinoic acid-inducible neural specific protein-3 is expressed in gonadotrope cell pituitary adenomas and induces proliferation, migration, and invasion.

Lynnette Shorts-Cary1, Mei Xu, Jessica Ertel, B K Kleinschmidt-Demasters, Kevin Lillehei, Ichiro Matsuoka, Sheila Nielsen-Preiss, Margaret E Wierman.   

Abstract

Pituitary tumors are common intracranial neoplasms that often result in endocrine dysfunction due to hormone overproduction or deficiencies from mass effects. Gonadotrope cell or gonadotropinomas are tumors that produce LH and/or FSH and represent 40% of macroadenomas. Little is known about their underlying pathogenic mechanisms. We compared expression profiles of 10 gonadotropinomas with nine normal pituitaries by cDNA array and identified bone morphogenetic protein- and retinoic acid-inducible neural-specific protein-3 (BRINP3) as overexpressed in tumors, compared with normals. BRINP3 is a novel, normally brain restricted protein of unknown function. BRINP3 mRNA was expressed selectively in gonadotropinomas. Subcellular localization studies showed that BRINP3 was targeted to the mitochondria, but BRINP3 overexpression was unable to protect pituitary cells against programmed cell death induced by growth factor withdrawal. However, BRINP3 overexpression in pituitary gonadotrope cells promoted proliferation, migration, and invasion. A BRINP3 antibody was raised that demonstrated clustered expression of BRINP3 protein in gonadotropinomas and not in normal human pituitary samples. Thus, BRINP3 is a mitochondrially localized protein that is selectively up-regulated in human gonadotropinomas. Its actions to increase proliferation, migration, and invasion suggest it may play an important role in pituitary tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17138656     DOI: 10.1210/en.2006-0905

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  24 in total

1.  Structure-Based Screen Identification of a Mammalian Ste20-like Kinase 4 (MST4) Inhibitor with Therapeutic Potential for Pituitary Tumors.

Authors:  Weipeng Xiong; Christopher J Matheson; Mei Xu; Donald S Backos; Taylor S Mills; Smita Salian-Mehta; Katja Kiseljak-Vassiliades; Philip Reigan; Margaret E Wierman
Journal:  Mol Cancer Ther       Date:  2015-12-31       Impact factor: 6.261

Review 2.  Pathogenesis of pituitary tumors.

Authors:  Shlomo Melmed
Journal:  Nat Rev Endocrinol       Date:  2011-03-22       Impact factor: 43.330

3.  Identification of growth arrest and DNA-damage-inducible gene beta (GADD45beta) as a novel tumor suppressor in pituitary gonadotrope tumors.

Authors:  Katherine A Michaelis; Aaron J Knox; Mei Xu; Katja Kiseljak-Vassiliades; Michael G Edwards; Mark Geraci; B K Kleinschmidt-DeMasters; Kevin O Lillehei; Margaret E Wierman
Journal:  Endocrinology       Date:  2011-08-02       Impact factor: 4.736

Review 4.  Isolation and characterization of novel pituitary tumor related genes: a cDNA representational difference approach.

Authors:  Xun Zhang; Yunli Zhou; Anne Klibanski
Journal:  Mol Cell Endocrinol       Date:  2010-03-06       Impact factor: 4.102

5.  Drug release kinetics, cell uptake, and tumor toxicity of hybrid VVVVVVKK peptide-assembled polylactide nanoparticles.

Authors:  Esmaiel Jabbari; Xiaoming Yang; Seyedsina Moeinzadeh; Xuezhong He
Journal:  Eur J Pharm Biopharm       Date:  2012-12-27       Impact factor: 5.571

Review 6.  Epidemiology and etiopathogenesis of pituitary adenomas.

Authors:  Elena D Aflorei; Márta Korbonits
Journal:  J Neurooncol       Date:  2014-01-31       Impact factor: 4.130

7.  Elucidating the Role of the Desmosome Protein p53 Apoptosis Effector Related to PMP-22 in Growth Hormone Tumors.

Authors:  Katja Kiseljak-Vassiliades; Taylor S Mills; Yu Zhang; Mei Xu; Kevin O Lillehei; B K Kleinschmidt-DeMasters; Margaret E Wierman
Journal:  Endocrinology       Date:  2017-05-01       Impact factor: 4.736

8.  Mammalian Ste20-like kinase 4 promotes pituitary cell proliferation and survival under hypoxia.

Authors:  Weipeng Xiong; Aaron J Knox; Mei Xu; Katja Kiseljak-Vassiliades; Sean P Colgan; Kelley S Brodsky; Bette K Kleinschmidt-Demasters; Kevin O Lillehei; Margaret E Wierman
Journal:  Mol Endocrinol       Date:  2015-02-04

9.  FAM5C contributes to aggressive periodontitis.

Authors:  Flavia M Carvalho; Eduardo M B Tinoco; Kathleen Deeley; Poliana M Duarte; Marcelo Faveri; Marcelo R Marques; Adriana C Mendonça; Xiaojing Wang; Karen Cuenco; Renato Menezes; Gustavo P Garlet; Alexandre R Vieira
Journal:  PLoS One       Date:  2010-04-07       Impact factor: 3.240

10.  Reprimo (RPRM) is a novel tumor suppressor in pituitary tumors and regulates survival, proliferation, and tumorigenicity.

Authors:  Mei Xu; Aaron J Knox; Katherine A Michaelis; Katja Kiseljak-Vassiliades; Bette K Kleinschmidt-DeMasters; Kevin O Lillehei; Margaret E Wierman
Journal:  Endocrinology       Date:  2012-05-04       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.